Vesilute

Dosing from the Literature

Published for the bladder: no dose in a peer-reviewed study; a 2009 patent injected 1 µg to 5 mg a day for 10 days, and the Russian label gives 100 µg capsules. Not published: any test of the capsules.

No peer-reviewed study has given Vesilute to anyone at any dose. The rows record what its developers’ patent and the Russian supplement label state, by source. They are stated regimens, not recommendations.

What It Is

Vesilute, spelled Vesilut by its developers (Везилют in Russian), is the dipeptide Glu-Asp: glutamic acid joined to aspartic acid, written ED, formula C9H14N2O7, 262.2 g/mol (PubChem). That is how the Khavinson group describes it. A 2020 review by Vladimir Khavinson says the dipeptide Glu-Asp, “named Vesilut,” was found by chromatography–mass spectrometry in a bladder-wall peptide preparation the group was testing as a medicine, and that “the preparation” raises the tone of the bladder’s smooth muscle and helps normalize its sphincter and detrusor. The passage cites only the group’s 2009 patent, which describes making and testing the dipeptide, not finding it in the extract (Khavinson, Klin Med 2020). A 2022 review by the group lists “Vesilut (ED)” as a “Bladder regulator,” with no study cited for it (Khavinson et al., Int J Mol Sci 2022; PMID 35887081).

It is not Vesugen. The same 2022 table lists Vesugen separately, as the tripeptide Lys-Glu-Asp (KED), a vasoprotector, and the group’s 2021 review of its peptides names KED as Vesugen and does not list Vesilut (Khavinson et al., Molecules 2021; PMID 34834147). No source found calls Vesilute KED. One 2010 abstract from the same institute printed Vesilut as H-Gly-Asp-OH, Gly-Asp (Grabezhev et al., Klin Gerontol 2010); the patent, the 2020 review and the 2022 table all give Glu-Asp.

In Russia it is sold as a dietary supplement, not a medicine: 0.2 g capsules, each with 100 µg of a “peptide complex” of glutamic and aspartic acid, which the label recommends for urination problems, chronic cystitis, chronic prostatitis and prostate enlargement, especially around menopause and in older people. Outside Russia, research-chemical sellers list 10–20 mg vials of Glu-Asp powder.

What has not been published: any peer-reviewed study of Vesilute in animals or people, its half-life, and whether any of an oral dose reaches the blood intact. PubMed returns no paper on it by name, Europe PMC’s full-text search finds only the 2022 table, and ClinicalTrials.gov has no record (searched October 3, 2026).

Who Khavinson was, and what his record supports →

Mechanism of Action

No mechanism study of Vesilute exists. Below are what its developers claim, what their patent measured, and the one peer-reviewed lab test of the Glu-Asp dipeptide.

• Bladder muscle tone (claimed) — The 2020 review says “the preparation” raises bladder smooth-muscle tone and helps normalize the sphincter and detrusor, without saying whether it means the dipeptide or the extract, and cites only the patent (Khavinson, Klin Med 2020).
• Bladder-muscle strips (patent) — In strips of rat bladder muscle in a bath, the peptide raised peak tension from 91.6 to 241.2 g/cm², about 2.6 times, at the top concentration, given as 100 µg/mL (the same passage lists 1–20 µg/mL as the concentrations added) (patent RU 2367467).
• Bladder-wall tissue in culture (patent) — In 26 fragments of rat bladder wall, 100 ng/mL made the explants grow 25% more than controls by day 3, and about as much at day 7 (patent RU 2367467).
• Binding to DNA (peer reviewed, in a test tube) — The Khavinson framework says short peptides act by binding DNA. In the group’s own computer search of all 800 dipeptides, ED had no predicted binding site in double-stranded DNA, and in a gel-shift test of four dipeptides it bound least (Kolchina et al., Nucleic Acids Res 2019; PMID 31598715).
• Entry into cells (computer only) — In the group’s docking calculations, ED was among the stronger predicted fits for the LAT1 and LAT2 amino-acid transporters (Khavinson et al., Int J Mol Sci 2022; Khavinson et al., Biomolecules 2023; PMID 36979488). Docking predicts a fit; it does not measure uptake.
• Oral uptake (not measured) — No study has measured Glu-Asp in the blood after a capsule.

What the Research Shows

• Rat bladder tissue (patent, 2009) — Explants grew 25% more at 100 ng/mL; detrusor strips contracted up to about 2.6 times harder (patent RU 2367467). Neither result has been published in a journal.
• Animal safety tests (patent, 2009) — Single intramuscular doses up to 5 mg/kg in 60 mice, and daily doses up to 1 mg/kg for 90 days in 50 rats and for 6 months in 76 guinea pigs; the patent reports no toxic effects and no changes in blood counts or organs (patent RU 2367467).
• Human thymus cells (2010 abstract) — A half-page abstract reported that Vesilut, printed there as Gly-Asp, and Vesugen raised the activation markers CD54 and HLA-DR on human thymus cells in culture, lowered their apoptosis and raised cytokine secretion by thymic epithelial cells. It gives no numbers or methods (Grabezhev et al., Klin Gerontol 2010).
• DNA binding (2019) — Weakest of four dipeptides in a gel-shift test, with no predicted binding site (Kolchina et al., Nucleic Acids Res 2019; PMID 31598715).
• Computer docking (2022, 2023) — Predicted fits to amino-acid and peptide transporters, not measurements (Khavinson et al., 2022; 2023).

Human Data

• No peer-reviewed human study — No journal has published a study giving Vesilute to people, and ClinicalTrials.gov lists none (searched October 3, 2026).
• The patent’s two comparisons (2009) — 56 men aged 24–45 with flaring chronic prostatitis and 67 adults aged 58–84 with frequent urination got standard treatment with or without daily injections of the peptide for 10 days (36 and 42 injected). The patent reports fewer night-time trips to urinate (from 4.2 to 1.6, and from 5.8 to 1.4, against 3.7 and 5.5 on standard treatment), urine-flow scores nearly doubled and no side effects. It describes randomization but no placebo or blinding, picked the dose by symptom severity, and was not peer reviewed (patent RU 2367467).
• The capsules — The capsules sold today have not been tested in any published study; the label says “results of clinical studies showed” the peptides relieve urination problems, but names none.
• A different product — The bladder-wall extract the group says Glu-Asp was found in has been in clinical trials of its own (Khavinson, Klin Med 2020); those trials test the extract, not Glu-Asp.

Reconstitution & Storage

No stability or reconstitution data have been published for Glu-Asp vials. The patent describes its synthesized peptide as a white, odorless powder (acetate salt), 98.33% pure by HPLC. The capsule label says to keep them dry, out of light, at room temperature.

• Identity — Vesilute is Glu-Asp, C9H14N2O7, 262.2 g/mol (PubChem); Vesugen’s tripeptide, Lys-Glu-Asp, is about 390. COA Check reads a lab report’s own numbers.
• Vials — No published storage or in-solution stability data; nothing on the page replaces a third-party lab report.

→ Calculator — vial-to-syringe math

Side Effects & Risks

• No peer-reviewed safety data — Nothing published in a journal has tested Vesilute’s safety.
• The patent’s claims — The patent reports no toxic effects in mice, rats and guinea pigs and no side effects in its patients; none of it was peer reviewed (patent RU 2367467).
• Label contraindications — The Russian label rules out use with intolerance of its ingredients, in pregnancy and while breastfeeding.
• Product identity — A research-chemical label is not proof of a vial’s contents. Glu-Asp’s mass is 262.2 g/mol (PubChem).
• Injection — If a vial is injected, sterile technique matters: contaminated reconstituted peptide is the most common practical risk with research-chemical peptides.
• WADA status — Not named on the 2026 Prohibited List; its S0 clause covers substances no other section names and no government has approved for human therapeutic use (World Anti-Doping Agency, 2026).
• Urinary symptoms — Infection, prostate disease and other bladder conditions cause the symptoms this supplement is sold for; a supplement is not a diagnosis.

Quick Compare — Vesilute vs Vesugen

Bloodwork & Monitoring

No published data: no study has measured any blood or urine marker in people taking Vesilute. The patent’s comparisons tracked how often people urinated and their urine flow. Urinary symptoms have causes a doctor can assess.

Commonly Stacked With

No published data: no combination with Vesilute has been studied.

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Legal Status

Related Compounds

People researching Vesilute often also look at these:

Next Steps

References

1. Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. Int J Mol Sci. 2022;23(14):7733. doi: 10.3390/ijms23147733. PMID: 35887081. (Table 2: “Vesilut (ED) … Bladder regulator.”)
2. Khavinson VKh. Peptide medicines: past, present, future. Klin Med (Mosk). 2020;98(3):165–177. doi: 10.30629/0023-2149-2020-98-3-165-177. (In Russian.)
3. Khavinson VKh, Malinin VV, Ryzhak GA, Kozlov LV, inventors. Pharmaceutical composition based on a peptide normalizing urination, and method of its use. Russian patent RU 2367467 C2; application filed November 26, 2007; published September 20, 2009. (In Russian.)
4. Grabezhev LA, Trofimov AV, Linkova NS, Polyakova VO. [Comparative effect of vesugen and vesilut on the restoration of thymus functions in aging]. Klin Gerontol. 2010;16(9-10):22. (In Russian; abstract.)
5. Kolchina N, Khavinson V, Linkova N, Yakimov A, Baitin D, Afanasyeva A, Petukhov M. Systematic search for structural motifs of peptide binding to double-stranded DNA. Nucleic Acids Res. 2019;47(20):10553-10563. doi: 10.1093/nar/gkz850. PMID: 31598715.
6. Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules. 2023;13(3):552. doi: 10.3390/biom13030552. PMID: 36979488.
7. Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22):7053. PMID: 34834147.
8. PubChem. Glu-Asp, CID 99716 (C9H14N2O7, 262.22 g/mol). pubchem.ncbi.nlm.nih.gov. Read October 3, 2026.
9. RLS Encyclopedia of Drugs. Vesilut® (dietary supplement): composition, category, directions and contraindications. rlsnet.ru/baa/vezilyut-34855. Read October 3, 2026. (In Russian.)
10. Vesilut® label: recommendations for use of the dietary supplement, state registration certificate 77.99.23.3.У.4252.5.08 of May 27, 2008. As reproduced at medi.ru/instrukciya/vezilyut_9574. Read October 3, 2026. (In Russian.)
11. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories 1–3). Updated May 14, 2026. fda.gov/media/94155/download.
12. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act (categories 1–3). Updated March 21, 2025. fda.gov/media/94164/download.
13. World Anti-Doping Agency. The 2026 Prohibited List. Section S0 (non-approved substances). wada-ama.org.
14. ClinicalTrials.gov. Searches for “Vesilute,” “Vesilut” and “Vezilut”: no records. October 3, 2026.
15. PubMed and Europe PMC. Searches for vesilute, vesilut, vezilut, vesilyut and Везилют, October 3, 2026: no PubMed records; one Europe PMC full-text mention (reference 1).
16. CyberLeninka (Russian scientific library). Search for “Везилют,” October 3, 2026: references 2 and 4.